Endo USA has recalled all unexpired lots of Adrenalin Chloride Solution epinephrine nasal solution, which is meant for topical application, due to FDA concerns about the potential for confusion of the product with the company's Adrenalin epinephrine for injection. As a result of the potential for confusion, Endo said, "FDA has determined the product to be misbranded … [Read more...] about Endo recalls epinephrine nasal solution after FDA determination that the product is misbranded
Business
Aridis announces that an unnamed pharma company has agreed to acquire AR-501 inhaled gallium
Aridis Pharmaceuticals said that "an undisclosed pharmaceutical company" has agreed to pay $6.5 million plus annual royalty payments for Aridis' AR-501 nebulized gallium for the treatment of chronic lung infections in patients with cystic fibrosis. Aridis said that it expects to receive 50% of the upfront payment by the end of the first quarter of 2025 and the other … [Read more...] about Aridis announces that an unnamed pharma company has agreed to acquire AR-501 inhaled gallium
Orexo and Abera partner on development of intranasal dry powder vaccines
Intranasal drug developer Orexo and Swedish vaccine developer Abera Bioscience have announced that they will collaborate on development of intranasal dry powder vaccines based on Orexo's AmorphOX powder engineering technology and Abera's vaccine platform, starting with an influenza vaccine. Abera will fund the project using grant money it has received from the … [Read more...] about Orexo and Abera partner on development of intranasal dry powder vaccines
Qnovia raises $16 million for continued development of QN-01 inhaled nicotine for smoking cessation
Qnovia announced that it has raised $16 million in Series B financing for development of its QN-01 nicotine inhaler for smoking cessation in the UK. In the US, the FDA recently approved Qnovia's IND for a new Phase 1 study of QN-01, which is delivered via a device based on the company's RespiRx vibrating mesh nebulizer technology. According to the announcement, … [Read more...] about Qnovia raises $16 million for continued development of QN-01 inhaled nicotine for smoking cessation
Virpax announces extension of NCATS R&D agreement for NES intranasal enkephalin
Virpax Pharmaceuticals announced the extension of a research and development agreement with an institute of the National Institutes of Health (NIH) related to the company's NES100 enkephalin nasal spray for the treatment of acute and chronic pain. NES100 is based on molecular envelope technology (MET) licensed from Nanomerics for delivery across the blood-brain … [Read more...] about Virpax announces extension of NCATS R&D agreement for NES intranasal enkephalin
Pulmatrix agrees to merge with Cullgen and will divest inhalation assets
Pulmatrix has announced a planned merger with biopharma Cullgen, which is developing oral protein degraders for the treatment of various indications. In anticipation of the merger, Pulmatrix says that it will divest inhalation assets, including PUR1800 inhaled dry powder narrow spectrum kinase inhibitor, PUR3100 inhaled dry powder DHE, and patents related to the … [Read more...] about Pulmatrix agrees to merge with Cullgen and will divest inhalation assets
ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world
Danish pharma company ALK says that it is paying ARS Pharmaceuticals $145 million up front and up to $320 million in potential milestone payments plus royalties for the rights to neffy intranasal adrenaline (epinephrine) everywhere except the US, Australia, New Zealand, Japan, and China. In addition to the marketing rights to neffy for the treatment of anaphylaxis, … [Read more...] about ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world
Polyrizon raises $4.2 million for continued development of its intranasal hydrogels
Intranasal hydrogel maker Polyrizon announced that it has closed a $4.2 million IPO, with a possibility of the total rising to $4.82 million if Aegis Capital exercises an option to purchase additional shares. Polyrizon said that funds from the IPO will be used for development of its hydrogel products for nasal drug delivery, called Capture and Contain (C&C), a … [Read more...] about Polyrizon raises $4.2 million for continued development of its intranasal hydrogels
AuraVax gets BARDA contract to test its NanoSTING-002 mucosal adjuvant with Codagenix’s intranasal flu vaccine
AuraVax Therapeutics announced that the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a preclinical research contract to support evaluation of AuraVax's NanoSTING-002 mucosal adjuvant with Codagenix's intranasal live attenuated influenza virus (LAIV). In early 2021, AuraVax announced … [Read more...] about AuraVax gets BARDA contract to test its NanoSTING-002 mucosal adjuvant with Codagenix’s intranasal flu vaccine
Vaxinano raises €6 million for development of intranasal vaccines
French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company's pipeline includes nasal vaccines against zoonotic diseases and parasites such as leishmaniasis and toxoplasmosis, with the majority of Vaxinano's vaccines … [Read more...] about Vaxinano raises €6 million for development of intranasal vaccines